Lumenis Splendor X
Dual-wavelength laser · 755+1064nm BLEND X square spot
Classification & configurations
Category group: Hair removal (diode, alexandrite, Nd:YAG, IPL)
At a glance
- New price
- $130k–$165kSource not documented
- Used asking price
- $70k–$110kSource not documented
- FDA status
- Supplies & recurring costs
- No per-treatment disposable; the cost is wear parts (lenses, flashlamp, protective windows, laser rods). Not published — Lumenis does not publish US wear-part pricing.
Sources and verified data on file
Data on file
- Recurring consumables
- Not verified
- Used asking prices
- Not verified
- This panel shows a per-treatment supply cost only when a recorded figure has a dated source.
- Bottle prices and estimates may still appear under Treatment & running costs.
- The calculator may include a labeled planning estimate. Review it or enter your own allowance; missing data never means $0.
Figures are reference points, not current offers. Used asking prices are not completed-sale values.
Read FDA-cleared indicationsExact wording from 2 FDA records
K241407 (Bios S.R.L., 2024)
The Nd:YAG 1064 Laser is intended for: • Removal of unwanted hair, for stable long term or permanent hair reduction and for treatment of Pseudofolliculitis barbae (PFB). Permanent hair reduction is defined as the long-term, stable reduction in the number of hairs regrowing when measured at 6, 9, and 12 months after the completion of a treatment regime. The lasers are indicated on all skin types, such as Fitzpatrick I-VI, including tanned skin. • Photocoagulation and hemostasis of benign pigmented and vascular lesions such as, but not limited to, port-wine stains, hemangioma, warts, telangiectasia, rosacea, venous lake, leg veins and spider veins. • Coagulation and hemostasis of soft tissue. • Treatment of benign pigmented lesions such as, but not limited to, lentigos (age spots), solar lentigos (sunspots), cafe au lait macules, seborrheic keratosis, nevi, chloasma, verrucae, skin tags, keratosis, tattoos (significant reduction in the intensity of black and/or blue-black tattoos) and plaques. The laser is indicated for benign pigmented lesions to reduce lesion size, for patients with benign lesions that would potentially benefit from aggressive treatment, and for patients with benign lesions that have not responded to other laser treatments. • Reduction of red pigmentation in hypertrophic and keloid scars where vascularity is an integral part of the scar. • Treatment of wrinkles. • Temporary increase of clear nail in patients with onychomycosis (e.g., dermatophytes, Trichophyton rubrum and T. mentagrophytes, and/or yeast Candida Albicans, etc.). The Alexandrite 755 laser is intended for: • Temporary hair reduction. • Stable long-term or permanent hair reduction through selective targeting of melanin in hair follicles. Permanent hair reduction is defined as the long-term, stable reduction in the number of hairs regrowing when measured at 6, 9, and 12 months after the completion of a treatment regime. On all skin types, such as Fitzpatrick I – VI, including tanned skin. • Treatment of benign pigmented lesions. • Treatment of wrinkles. • Photocoagulation of dermatological benign vascular lesions (such as port-wine stains, hemangiomas, telangiectasias).
Verbatim from the FDA 510(k) summary, retrieved 8 Sep 2026.
K243445 (Bios S.R.L., 2024)
The Nd:YAG 1064 Laser is intended for: • Removal of unwanted hair, for stable long term or permanent hair reduction and for treatment of Pseudofolliculitis Barbae (PFB). Permanent hair reduction is defined as the long-term, stable reduction in the number of hairs regrowing when measured at 6, 9, and 12 months after the completion of a treatment regime. The lasers are indicated on all skin types, such as Fitzpatrick I-VI, including tanned skin. • Photocoagulation and hemostasis of benign pigmented and vascular lesions such as but not limited to port-wine stains, hemangioma, warts, telangiectasia, rosacea, venus lake, leg veins and spider veins. • Coagulation and hemostasis of soft tissue. • Treatment of benign pigmented lesions such as, but not limited to, lentigos (age spots), solar lentigos (sunspots cafè au lait macules, seborrheic keratosis, nevi, chloasma, verrucae, skin tags, keratosis), tattoos (significant reduction in the intensity of black and/or blue-black tattoos) and plaques. The laser is indicated for benign pigmented lesions to reduce lesion size, for patients with benign lesions that would potentially benefit from aggressive treatment, and for patients with benign lesions that have not responded to other laser treatments. • Reduction of red pigmentation in hypertrophic and keloid scars where vascularity is an integral part of the scar. • Treatment of wrinkles. • Temporary increase of clear nail in patients with onychomycosis (e.g., dermatophytes, Trichophyton rubrum and T. mentagrophytes, and for yeast Candida Albicans, etc.). The Alexandrite 755 laser is intended for: • Temporary hair reduction. • Stable long-term or permanent hair reduction through selective targeting of melanin in hair follicles. Permanent hair reduction is defined as the long-term, stable reduction in the number of hairs regrowing when measured at 6, 9, and 12 months after the completion of a treatment regime. On all skin types, such as Fitzpatrick I – VI, including tanned skin. • Treatment of benign pigmented lesions. • Treatment of wrinkles. • Photocoagulation of dermatological benign vascular lesions (such as port-wine stains, hemangiomas, telangiectasias). The Alex+Nd:YAG (755 + 1064 lasers) is intended for: • Stable long-term or permanent hair reduction through selecting targeting of melanin in hair follicles.
Verbatim from the FDA 510(k) summary, retrieved 8 Sep 2026.
Page updated: September 7, 2026 · How we verify
Axis runs $0–$165k. Reference figures, not current offers. Used asking prices are not completed-sale values.
Not verified
We hold no per-treatment consumable price for this device from a dated source. Ask the seller for a written per-treatment cost.
Price sourcesSources, dates and configurations
Key factsCompany, specifications and verification dates
| Manufacturer | Lumenis |
|---|---|
| Company | Owner: Baring Private Equity Asia (BPEA, now part of EQT) (private equity owned, since 2019) · Distribution: direct |
| Parent company | Lumenis |
| Brand owner | Lumenis |
| Built by (OEM) | Lumenis Be Ltd. |
| Category | Dual-wavelength laser |
| Technology | 755+1064nm BLEND X square spot |
| FDA status | FDA Cleared |
| 510(k) citation | K241407, K243445 |
| New price range | $130k–$165k |
| Used asking range | $70k–$110k |
| Consumables | No per-treatment disposable; the cost is wear parts (lenses, flashlamp, protective windows, laser rods). Not published — Lumenis does not publish US wear-part pricing. |
| Launch year | 2018 |
| Pricing | Not published |
| Manufacturer-source documents checked | Not published |
Overview
Simultaneous blended alex/YAG, very fast
How it worksTechnology and manufacturing
How the technology works
Solid-state platform housing both a 755nm Alexandrite and a 1064nm Nd:YAG firing sequentially or simultaneously, with the operator dialing the energy ratio — effectively a slider from light-skin/fine-hair to dark-skin/deep-follicle.
Square spots tile without the overlap/gap compromise of round spots, which is the source of both speed and uniformity. Also cleared for pigmented and vascular lesions and wrinkles on the Nd:YAG side.
Patented technology
BLEND X — simultaneous ratio-adjustable emission of 755nm and 1064nm in a single pulse rather than choosing one per pass; high-repetition square-spot delivery is the other half of the proprietary story.
Origin
Yokneam, Israel (Lumenis / Lumenis Be).
FDA & regulatory detailClearance timeline, authorization route and citation notes
FDA-cleared indications (verbatim)
K241407 (Bios S.R.L., 2024)
The Nd:YAG 1064 Laser is intended for: • Removal of unwanted hair, for stable long term or permanent hair reduction and for treatment of Pseudofolliculitis barbae (PFB). Permanent hair reduction is defined as the long-term, stable reduction in the number of hairs regrowing when measured at 6, 9, and 12 months after the completion of a treatment regime. The lasers are indicated on all skin types, such as Fitzpatrick I-VI, including tanned skin. • Photocoagulation and hemostasis of benign pigmented and vascular lesions such as, but not limited to, port-wine stains, hemangioma, warts, telangiectasia, rosacea, venous lake, leg veins and spider veins. • Coagulation and hemostasis of soft tissue. • Treatment of benign pigmented lesions such as, but not limited to, lentigos (age spots), solar lentigos (sunspots), cafe au lait macules, seborrheic keratosis, nevi, chloasma, verrucae, skin tags, keratosis, tattoos (significant reduction in the intensity of black and/or blue-black tattoos) and plaques. The laser is indicated for benign pigmented lesions to reduce lesion size, for patients with benign lesions that would potentially benefit from aggressive treatment, and for patients with benign lesions that have not responded to other laser treatments. • Reduction of red pigmentation in hypertrophic and keloid scars where vascularity is an integral part of the scar. • Treatment of wrinkles. • Temporary increase of clear nail in patients with onychomycosis (e.g., dermatophytes, Trichophyton rubrum and T. mentagrophytes, and/or yeast Candida Albicans, etc.). The Alexandrite 755 laser is intended for: • Temporary hair reduction. • Stable long-term or permanent hair reduction through selective targeting of melanin in hair follicles. Permanent hair reduction is defined as the long-term, stable reduction in the number of hairs regrowing when measured at 6, 9, and 12 months after the completion of a treatment regime. On all skin types, such as Fitzpatrick I – VI, including tanned skin. • Treatment of benign pigmented lesions. • Treatment of wrinkles. • Photocoagulation of dermatological benign vascular lesions (such as port-wine stains, hemangiomas, telangiectasias).
Verbatim from the FDA 510(k) summary, retrieved 8 Sep 2026.
K243445 (Bios S.R.L., 2024)
The Nd:YAG 1064 Laser is intended for: • Removal of unwanted hair, for stable long term or permanent hair reduction and for treatment of Pseudofolliculitis Barbae (PFB). Permanent hair reduction is defined as the long-term, stable reduction in the number of hairs regrowing when measured at 6, 9, and 12 months after the completion of a treatment regime. The lasers are indicated on all skin types, such as Fitzpatrick I-VI, including tanned skin. • Photocoagulation and hemostasis of benign pigmented and vascular lesions such as but not limited to port-wine stains, hemangioma, warts, telangiectasia, rosacea, venus lake, leg veins and spider veins. • Coagulation and hemostasis of soft tissue. • Treatment of benign pigmented lesions such as, but not limited to, lentigos (age spots), solar lentigos (sunspots cafè au lait macules, seborrheic keratosis, nevi, chloasma, verrucae, skin tags, keratosis), tattoos (significant reduction in the intensity of black and/or blue-black tattoos) and plaques. The laser is indicated for benign pigmented lesions to reduce lesion size, for patients with benign lesions that would potentially benefit from aggressive treatment, and for patients with benign lesions that have not responded to other laser treatments. • Reduction of red pigmentation in hypertrophic and keloid scars where vascularity is an integral part of the scar. • Treatment of wrinkles. • Temporary increase of clear nail in patients with onychomycosis (e.g., dermatophytes, Trichophyton rubrum and T. mentagrophytes, and for yeast Candida Albicans, etc.). The Alexandrite 755 laser is intended for: • Temporary hair reduction. • Stable long-term or permanent hair reduction through selective targeting of melanin in hair follicles. Permanent hair reduction is defined as the long-term, stable reduction in the number of hairs regrowing when measured at 6, 9, and 12 months after the completion of a treatment regime. On all skin types, such as Fitzpatrick I – VI, including tanned skin. • Treatment of benign pigmented lesions. • Treatment of wrinkles. • Photocoagulation of dermatological benign vascular lesions (such as port-wine stains, hemangiomas, telangiectasias). The Alex+Nd:YAG (755 + 1064 lasers) is intended for: • Stable long-term or permanent hair reduction through selecting targeting of melanin in hair follicles.
Verbatim from the FDA 510(k) summary, retrieved 8 Sep 2026.
Marketed for
Dual-wavelength laser — 755+1064nm BLEND X square spot
Marketing claims are the manufacturer's own and are not the same as a cleared indication.
510(k) holder of record
510(k) holder of record: Bios S.R.L. — Lumenis markets, supports and warranties the device in the US.
Parent company: Lumenis
Legal manufacturer: Lumenis Be Ltd. (Israel)
Applicant on the FDA record
Bios S.R.L.The applicant named on the FDA record can differ from the brand shown on the device.
Regulatory data comes from public FDA records and may lag recent updates. Confirm the applicable status and documentation before purchase.
Treatment & running costs
Treatments
Sessions & timing
No treatment schedule documented yet.
What practices charge
No sourced treatment price on file.
Supplies & recurring costs
No per-treatment disposable. The recurring cost is wear parts — handpiece lenses, flashlamp, protective windows, ceramic reflector, Nd:YAG and alexandrite rods, fibre window.
Not published — Lumenis does not publish US wear-part pricing and the figures previously shown carried no dated source.
Source notes
LaserGCC parts catalog and Innovative Optics eye-shield listing. 30 Aug 2026 research pass.
Additional supply notes
No per-treatment disposable; the cost is wear parts (lenses, flashlamp, protective windows, laser rods). Not published — Lumenis does not publish US wear-part pricing.
Annual service & support
No annual service cost documented yet.
Payback calculatorModel your own volume, labor and service costs
Estimate your payback
Pre-filled from our published Lumenis Splendor X data where we have it. Estimates appear once the required inputs are available. Review and adjust every pre-filled value before relying on the result.
Start from
No verified per-treatment supply cost is on file. Enter your own allowance. Use $0 only if you have confirmed that it applies to your practice.
Pre-filled from the midpoint of the published new-price range
20 is an illustrative default — change it to your volume.
No sourced per-session price on file — enter what you charge.
Required — enter your cost; missing data does not mean $0.
Provider or tech time for one treatment, fully loaded. Enter 0 if you own-operate.
Annual service contract ÷ 12, if you carry one.
Your estimate
Enter price you charge per treatment, consumable cost per treatment to see contribution and a payback range.
This model ignores financing — if you lease or borrow, add your monthly payment. Estimates from your inputs and our published ranges — not a projection, guarantee or financial advice. How we calculate this.
ComplianceScreening and contraindications on the manufacturer's record
Contraindications & screening
Standard screen — pregnancy, active tan (be conservative with the Alexandrite fraction), photosensitizers, recent isotretinoin, active infection, tattoos in field, suspicious lesions — and high power output means operator training matters more than on gentler platforms.
Warranty & serviceWhat to confirm in writing before you buy
Before buying new or used, confirm in writing:
- Current warranty coverage
- Included training
- Service terms
Chains using this device
A chain listing does not establish availability at every location.
No confirmed chain deployments recorded yet.
Owner & operator reviews
Write a reviewNo owner or operator reviews yet. Be the first →
Current alternatives
Current catalog models to research. Confirm availability and configuration with the supplier.
History2 tracked changes
Every tracked change to pricing, lifecycle status, FDA data and warranty terms — newest first.
September 7, 2026
science
Source: Catalog update — editorial sentences removed (neutral-voice standard, 7 Sep 2026)
August 1, 2026
Record created
Added to The Aesthetic Index — August 2026
Source: The Aesthetic Index editorial
Cite this data: The Aesthetic Index, "Lumenis Splendor X — pricing, FDA status and cost to own", aestheticindex.co (accessed September 24, 2026).
Get the full State of Aesthetic Devices 2026 report
A catalog of US-marketed aesthetic and wellness devices — preview it free.
Device and company names are trademarks of their respective owners. The Aesthetic Index is not affiliated with or endorsed by any manufacturer, distributor or lender named here, except as disclosed. Price figures are references, not current offers. Check each device’s source notes. Not medical, legal or regulatory advice.